TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06526299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo SPECT/CT and CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Vipivotide Tetraxetan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET-CT Scan
Description: Undergo PSMA PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT
Study: NCT06742788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Description: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) is an emerging, non-invasive adjunctive therapy.~The taVNS protocol is set at a pulse width of 500 µs and a frequency of 25 Hz, with an intensity value of 5 mA. The stimulation is to be carried out for a total of 2 hours daily, with the sessions divided into four parts, each lasting 30 minutes. At least one of these periods occur within 2 hours before bedtime.~The study will use the Chinese National Institutes for Food and Drug Control certificated taVNS device TVNS-100 (Xinzhile Medical Technology Co., Jiangxi, China). The study includes an intervening period of 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcutaneous auricular vagus nerve stimulation (staVNS)
Description: The sham transcutaneous auricular vagus nerve stimulation (staVNS) serves as a sub-threshold therapeutic stimulus functions as a sham stimulus. The staVNS protocol is set at a pulse width of 500 µs and a frequency of 1 Hz, with an intensity value of 5 mA. The stimulation is to be carried out for a total of 2 hours daily, with the sessions divided into four parts, each lasting 30 minutes. At least one of these periods occur within 2 hours before bedtime. The study will use the Chinese National Institutes for Food and Drug Control certificated taVNS device TVNS-100 (Xinzhile Medical Technology Co., Jiangxi, China). The study includes an intervening period of 4 weeks.
Study: NCT06744205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
Description: * Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
Description: * Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
Description: * Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
Description: * Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
Description: * Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
Description: * Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection
Study: NCT06469450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: one 40 mg atorvastatin tablet once daily for 28 days
Study: NCT06744205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
Description: * Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV mRNA-neuraminidase (NA)
Description: * Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV mRNA-neuraminidase (NA)
Description: * Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV mRNA-neuraminidase (NA)
Description: * Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV mRNA-neuraminidase (NA)
Description: * Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV mRNA-neuraminidase (NA)
Description: * Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV mRNA-neuraminidase (NA)
Description: * Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV mRNA-neuraminidase (NA)
Description: * Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV mRNA-HA Vaccine 2
Description: * Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Influenza Standard Dose Vaccine
Description: * Pharmaceutical form: Liquid suspension for injection in pre-filled syringe~* Route of administration: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Influenza Vaccine High Dose
Description: * Pharmaceutical form: Liquid suspension for injection in pre-filled syringe~* Route of administration: Intramuscular injection
Study: NCT06747923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB17170
Description: Taking SB17170 orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB17170
Description: Taking SB17170 orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking Placebo orally once a day
Study: NCT06744062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1015
Description: One tablet administered alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1015-1
Description: One tablet administered alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1015-2
Description: One tablet administered alone
Study: NCT06742086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Tablet
Study: NCT06753838

Intervention type: BIOLOGICAL
Intervention: Sampling of 3 additional BAPA tubes
Description: the 3 additional tubes will be taken at the same time as the blood sample taken for the routine PFA test
Study: NCT06760819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088
Description: tablet, oral
Study: NCT06764628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-4375
Description: SHR-4375 injection
Study: NCT06766604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Super-GDF9 supplementation during CAPA-IVM
Description: Group 1: donated COCs will be exposed to Super-GDF9 at 50 ng/ml in both the CAPACITATION and MATURATION culture steps.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CAPA-IVM
Description: Group 2: The subject's remaining COCs will be cultured in the CAPA step and the IVM step without the addition of Super-GDF9 during CAPA-IVM.
Study: NCT06776471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resin-based flowable filling material
Description: Preventive restoration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin-based flowable filling material
Description: Preventive restoration
Study: NCT05799430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary medication review
Description: FP communicate to the PCP patients recently discharged. The medication review process consists in 5 steps:~1. PCP perform a structured drug review based on information from health record and e-prescribing application. The drug review comprise the appraisal of potentially inappropriate medication based on lists of explicit criteria.~2. PCP communicates and discuss the results of medication review with GP and PCN, in a brief meeting face-to-face, with possible adaptation of the recommendations.~3. FP, PCN and PCP agree on a personalized therapeutic plan for the patient that includes actions to optimize the therapy.~4. FP and PCN share plan with the patient and/or carer with possible adaptation of the recommendations and agree about actions to be implemented.~5. FP and PCN communicate to PCP final agreement with patient and/or carer~6. FP and/or PCN follow-up implantation of agreed recommendations using standard health care procedures
Study: NCT06776900

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supine position
Description: An assistant will be asked to hold the tongue in protrusion using a gauze held by a Magill forceps (preventing it from falling backwards). The operator will introduce the bronchoscope orally allowing its advancement till it reaches the laryngeal inlet. The glottic view will be graded from 1 (larynx is only seen) to 5 (the epiglottis down folded and larynx cannot be seen directly) (10).~The scope will be manipulated to pass between the 2 vocal cords, and then advanced till the carina is seen to glide the suitable ETT into the trachea. Once the ETT is connected to the mechanical ventilator, chest auscultation and capnography waves will be used to confirm a successful intubation.~At any intubation attempt where SpO2 reaches 90%, the procedure will be suspended and mechanical ventilation via a facemask applied till SpO2 of 100% achieved.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral position
Description: An assistant will be asked to hold the tongue in protrusion using a gauze held by a Magill forceps (preventing it from falling backwards). The operator will introduce the bronchoscope orally allowing its advancement till it reaches the laryngeal inlet. The glottic view will be graded from 1 (larynx is only seen) to 5 (the epiglottis down folded and larynx cannot be seen directly) (10).~The scope will be manipulated to pass between the 2 vocal cords, and then advanced till the carina is seen to glide the suitable ETT into the trachea. Once the ETT is connected to the mechanical ventilator, chest auscultation and capnography waves will be used to confirm a successful intubation.~At any intubation attempt where SpO2 reaches 90%, the procedure will be suspended and mechanical ventilation via a facemask applied till SpO2 of 100% achieved.
Study: NCT06771726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RedScar App
Description: use of the RedScar© app on patients' smartphones. Patients will complete a brief health questionnaire and upload a wound photograph to the app, which will provide recommendations based on the risk of infection detected. Simultaneously, an in-person wound assessment will be conducted by the investigator to compare results.
Study: NCT06256705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous 68Ga-DOTATOC PET-MRI
Description: on month before first cycle of 177Lu-DOTATATE, after second cycle and one year after first cycle
Study: NCT04404153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS.
Description: At-home remotely supervised tDCS delivered over the dorsolateral prefrontal cortex with the anode on the left, cathode on the right, at an intensity of 2 mA, delivered for 30 minutes five times per week (Monday-Friday) for 26 weeks (6 months).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver sham tDCS.
Description: Sham treatment will consist of the current ramped up to 2mA over 30 seconds, ramped down over 30 seconds and stay at 0 current for the remaining time of the 30-minute application period five times per week (Monday-Friday) for 26 weeks (6 months).
Study: NCT06772415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GenSci122 tablet 50mg
Description: Orally Once Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GenSci122 tablet 250mg
Description: Orally Once Daily
Study: NCT06778499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training for experimental group
Description: The experimental groups will undergo 3 interventions a week, with one session lasting 90 minutes. The experimental group will perform 15 minutes of dynamic stretching, 30 minutes of Latin dance-specific technique training, 30 minutes of plyometric training, and 15 minutes of relaxation stretching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional training for control group
Description: The control group will perform 15 minutes of dynamic stretching, 30 minutes of Latin dance-specific technique training, 30 minutes of general training, and 15 minutes of relaxation stretching.
Study: NCT05065047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Given by IV
Study: NCT05799430

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Usual care by FP an PCN
Study: NCT05337553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taldefgrobep alfa
Description: DB Phase: 35 mg/50 mg weekly subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DB Phase: matching placebo 35 mg/50 mg weekly subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: taldefgrobep alfa
Description: Extension Phase: 35 mg/50 mg weekly subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taldefgrobep alfa
Description: Extension Phase: 35 mg/50 mg weekly subcutaneous injection
Study: NCT06612801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The REThink Game
Description: REThink is an online therapeutic game designed to improve the emotional well-being of young people, based on the principles of Rational Emotive Behavior Therapy (REBT). The game features a character named RETMAN, who leads players through seven levels, each dedicated to teaching a particular emotional regulation skill. Each level consists of three sub-levels that gradually become more challenging. REThink can be utilized as a standalone intervention, as a complement to self-help psychotherapeutic methods, or for focused skills training in emotional regulation. Each level trains a specific emoion-regulation skills such as emotion recognition, relaxation, cognitive change, problem solving, compassion and self-compassion.
Study: NCT06611930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-0045
Description: Interleukin-22 agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-0045
Description: Interleukin-22 agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (liquid for injection, which includes no active ingredient).
Study: NCT06215066

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Progressive Muscle Relaxation Exercise
Description: The modified progressive muscle relaxation technique will be applied through muscle relaxation to a specific part of the body.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The virtual reality box
Description: a virtual reality box (VR- box) with 3D glasses (eye goggles)
Study: NCT04825951

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CS 2000
Description: treating growing Skeletal growing Class III patients
Study: NCT05137314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLG0206
Description: PLG0206 is an engineered antibacterial peptide (EAP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLG0206
Description: PLG0206 is an engineered antibacterial peptide (EAP)
Study: NCT05942820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BWC0977
Description: SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days.
Study: NCT04959864

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isitol®
Description: 1 sachet of Isitol® (2,1g) contains :~* 1000 mg of myo-inositol ;~* 300 mg of N-acetyl-cystein ;~* 48.5 mg of zinc citrate (equivalent zinc pure element : 15 mg) ;~* 35 mg of D-a-tocopherol (equivalent vitamin E pure element : 12 mg) ;~* 16 mg of vitamin B3 ;~* 1.8 mg of pyridoxin hydrochloride (equivalent vitamin B6 pure element : 1.4 mg) ;~* 1.4 mg of vitamin B2 ;~* 0.37 mg of (6S)-5-methyltetrahydrofolic acid, glucosamine salt (equivalent vitamin B9 pure element : 0.2 mg).~Sachets are packaged in box of 30.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet of placebo (2,1g) contains :~* 1765.1 of maltodextrin ;~* 300 mg of magnesium carbonate ;~* 40 mg of citric acid ;~* 5.3 mg of beta-carotene ;~* 2.16 mg of silicon dioxide ;~* 1.44 mg of sucralose.~Sachets are packaged in box of 30.
Study: NCT06412848

Intervention type: DRUG
Intervention: Avelumab
Description: This is an observational study, participants who received avelumab as first line maintenance therapy after a PBCT.
Study: NCT05942820

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAD Cohorts: Two participants in each cohort will receive a matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.~Other Names:~• Compounded solution minus BWC0977
Study: NCT05143632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearSight
Description: The primary hypothesis is that continuous non-invasive monitoring using ClearSight reduces the incidence of intraoperative hypotensive events (defined by mean arterial pressure below a value of 65 mmHg for more than 1 minute) and the duration of the events themselves, leading to an improvement in patients' outcomes.
Study: NCT04092530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LINCC intervention - enable co-schedule feature
Description: Clinics will offer postpartum contraception appointments earlier and the opportunity to co-schedule these appointments with their infant's next well-baby visit
Study: NCT06503068

Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire in both digital and written forms in both Arabic and English versions.

Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire in both digital and written forms in both Arabic and English versions.
Study: NCT05138601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Collaborative Care Clinic
Description: Trained clinical pharmacists will monitor BP, prescribe and adjust medications and monitor for side effects of medications under the license of, and in communication with, the patient's physician.
Study: NCT05672316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study: NCT05575739

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of oxidative stress levels (Malondialdehide, glutathione disulphate, total antioxidant capacity, superoxide dismutase and carbonylated proteins )
Description: Follicular fluid and serum were obtained within 1 hour of oocyte recovery. Considerable care was taken to pool follicular fluid uncontaminated with blood. The samples were processed by centrifuge and 1-mL aliquots stored ar -80ºC until assay. Malondialdehide, glutathione disulphate, total antioxidant capacity, superoxide dismutase and carbonylated proteins were measured from follicular fluid and plasma according to manufacturer's protocol. This assay has been described as highly sensitive. Data were expressed as millimoles per liter from the reference curve.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of oxidative stress levels (Malondialdehide, glutathione disulphate, total antioxidant capacity, superoxide dismutase and carbonylated proteins )
Description: Follicular fluid and serum were obtained within 1 hour of oocyte recovery. Considerable care was taken to pool follicular fluid uncontaminated with blood. The samples were processed by centrifuge and 1-mL aliquots stored ar -80ºC until assay. Malondialdehide, glutathione disulphate, total antioxidant capacity, superoxide dismutase and carbonylated proteins were measured from follicular fluid and plasma according to manufacturer's protocol. This assay has been described as highly sensitive. Data were expressed as millimoles per liter from the reference curve.